ALTERATIONS OF THE P16 (MTS1) GENE IN TESTICULAR, OVARIAN, AND ENDOMETRIAL MALIGNANCIES

被引:44
作者
HATTA, Y
HIRAMA, T
TAKEUCHI, S
LEE, E
PHAM, E
MILLER, CW
STROHMEYER, T
WILCZYNSKI, SP
MELMED, S
KOEFFLER, HP
机构
[1] UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DIV ENDOCRINOL, LOS ANGELES, CA 90048 USA
[2] CITY HOPE NATL MED CTR, DEPT ANAT PATHOL, DUARTE, CA USA
[3] SCHERING AG, DEPT CLIN DEV ONCOL, BERLIN, GERMANY
关键词
OVARIAN NEOPLASMS; POLYMORPHISM; GENETICS; MUTATION; TESTICULAR NEOPLASMS; GENES; SUPPRESSOR; TUMOR;
D O I
10.1016/S0022-5347(01)66833-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The p16 (MTS1) gene codes for a cyclin-dependent kinase inhibitor and may be a new tumor suppressor gene. It is frequently mutated in a variety of cell lines established from tumors. This is the first report of screening for alteration of the p16 gene in testicular, ovarian and endometrial malignancies. Materials and Methods: We examined alterations of p16 in 78 primary genital tumors (42 testicular, 21 ovarian and 15 endometrial cancers) and mononuclear cells from 2 patients with Lynch syndrome II as well as 5 testicular tumor cell lines by single-strand conformation polymorphism (SSCP) and Southern blot hybridization. Results: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. Analysis of DNA sequence of these samples revealed a polymorphism at codon 140. Southern blot hybridization detected neither deletions nor rearrangements of the p16 gene in any of the samples. Conclusions: Taken together, these results suggest that p16 alterations probably are not important for tumorigenesis of testicular, ovarian and endometrial tumors.
引用
收藏
页码:1954 / 1957
页数:4
相关论文
共 48 条
[1]   ONCOGENESIS IN OVARIAN-CANCER [J].
BORRESEN, AL .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1992, 71 :25-30
[2]   RATES OF P16(MTS1) MUTATIONS IN PRIMARY TUMORS WITH 9P LOSS [J].
CAIRNS, P ;
MAO, L ;
MERLO, A ;
LEE, DJ ;
SCHWAB, D ;
EBY, Y ;
TOKINO, K ;
VANDERRIET, P ;
BLAUGRUND, JE ;
SIDRANSKY, D .
SCIENCE, 1994, 265 (5170) :415-416
[3]   FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA [J].
CALDAS, C ;
HAHN, SA ;
DACOSTA, LT ;
REDSTON, MS ;
SCHUTTE, M ;
SEYMOUR, AB ;
WEINSTEIN, CL ;
HRUBAN, RH ;
YEO, CJ ;
KERN, SE .
NATURE GENETICS, 1994, 8 (01) :27-32
[4]  
CHEN YC, 1990, BLOOD, V76, P2060
[5]  
CHIEN C, 1990, LIFE SCI, V14, P27
[6]  
DAMICO D, 1992, CANCER RES, V52, P1996
[7]  
DEVOS S, 1995, IN PRESS GENES CHROM
[8]   HIGH PREVALENCE OF MUTATIONS OF THE P53 GENE IN POORLY DIFFERENTIATED HUMAN THYROID CARCINOMAS [J].
FAGIN, JA ;
MATSUO, K ;
KARMAKAR, A ;
CHEN, DL ;
TANG, SH ;
KOEFFLER, HP .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :179-184
[9]  
FLEISCHHACKER M, 1994, MODERN PATHOL, V7, P435
[10]   DELETIONS OF THE CYCLIN-DEPENDENT KINASE INHIBITOR GENES P16(INK4A) AND P15(INK4B) IN NON-HODGKINS-LYMPHOMAS [J].
GOMBART, AF ;
MOROSETTI, R ;
MILLER, CW ;
SAID, JW ;
KOEFFLER, HP .
BLOOD, 1995, 86 (04) :1534-1539